Paradigm Biopharmaceuticals Ltd
ASX:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P N Gadgil Jewellers Ltd
NSE:PNGJL
|
IN |
Paradigm Biopharmaceuticals Ltd
Revenue
Paradigm Biopharmaceuticals Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Revenue
AU$7m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Revenue
$65.4m
|
CAGR 3-Years
93%
|
CAGR 5-Years
32%
|
CAGR 10-Years
13%
|
|
|
CSL Ltd
ASX:CSL
|
Revenue
$15.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Revenue
AU$3.4m
|
CAGR 3-Years
153%
|
CAGR 5-Years
189%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Revenue
AU$803.8m
|
CAGR 3-Years
98%
|
CAGR 5-Years
174%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Revenue
AU$24.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
55%
|
CAGR 10-Years
86%
|
|
Paradigm Biopharmaceuticals Ltd
Glance View
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
See Also
What is Paradigm Biopharmaceuticals Ltd's Revenue?
Revenue
7m
AUD
Based on the financial report for Dec 31, 2025, Paradigm Biopharmaceuticals Ltd's Revenue amounts to 7m AUD.
What is Paradigm Biopharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 5Y
11%
Over the last year, the Revenue growth was 4%. The average annual Revenue growth rates for Paradigm Biopharmaceuticals Ltd have been -8% over the past three years , 11% over the past five years .
